Investors’ Patience Is Being Tested Right Now By Mangoceuticals Inc (NASDAQ: MGRX)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Product.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Mangoceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Health Information Services industry. At the end of the last regular session, the stock closed at $0.41 and fluctuated between $0.4850 as its day high and $0.3799 as its day low. The current market capitalization of Mangoceuticals Inc is $6.88M. A total of 2.55 million shares were traded on the day, compared to an average of 648.45K shares.

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, MGRX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 3 BUYs and 0 SELLs from insiders. Insiders purchased 400,000 shares during that period but sold 0.

In the most recent transaction, Cohen Jacob D. bought 275,000 shares of MGRX for 1.00 per share on Apr 10. After the transaction, the Chief Executive Officer now owns 8,275,000 company shares.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, MGRX has a high of $4.37 and a low of $0.26.

As of this writing, MGRX has an earnings estimate of $Mangoceuticals, Inc. per share for the current quarter. EPS was calculated based on a consensus of MacroGenics, Inc. estimates, with a high estimate of $Agile Therapeutics, Inc. per share and a lower estimate of $Eagle Pharmaceuticals, Inc.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. MGRX’s latest balance sheet shows that the firm has $22.55k in Cash & Short Term Investments as of fiscal 2021. There were $39.27k in debt and $39.27k in liabilities at the time. Its Book Value Per Share was $0.08, while its Total Shareholder’s Equity was -$16.72k.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock.

Most Popular

Related Posts